Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

380 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
International real-world study of DLL3 expression in patients with small cell lung cancer.
Rojo F, Corassa M, Mavroudis D, Öz AB, Biesma B, Brcic L, Pauwels P, Sailer V, Gosney J, Miljkovic D, Hader C, Wu M, Almarez T, Penault-Llorca F. Rojo F, et al. Among authors: mavroudis d. Lung Cancer. 2020 Sep;147:237-243. doi: 10.1016/j.lungcan.2020.07.026. Epub 2020 Jul 27. Lung Cancer. 2020. PMID: 32745892 Free article.
Targeting angiogenesis in small cell lung cancer.
Stratigos M, Matikas A, Voutsina A, Mavroudis D, Georgoulias V. Stratigos M, et al. Among authors: mavroudis d. Transl Lung Cancer Res. 2016 Aug;5(4):389-400. doi: 10.21037/tlcr.2016.08.04. Transl Lung Cancer Res. 2016. PMID: 27652203 Free PMC article. Review.
Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study.
Rounis K, Makrakis D, Papadaki C, Monastirioti A, Vamvakas L, Kalbakis K, Gourlia K, Xanthopoulos I, Tsamardinos I, Mavroudis D, Agelaki S. Rounis K, et al. Among authors: mavroudis d. PLoS One. 2021 Jun 1;16(6):e0252537. doi: 10.1371/journal.pone.0252537. eCollection 2021. PLoS One. 2021. PMID: 34061904 Free PMC article.
Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece.
Lampaki S, Mountzios G, Georgoulias V, Rapti A, Xanthakis I, Baka S, Mavroudis D, Samantas E, Athanasiadis E, Zagouri F, Charpidou A, Somarakis A, Papista C, Nikolaou A, Anastasopoulou E, Paparepa Z, Syrigos KN. Lampaki S, et al. Among authors: mavroudis d. Future Oncol. 2022 Sep;18(28):3151-3164. doi: 10.2217/fon-2022-0386. Epub 2022 Aug 5. Future Oncol. 2022. PMID: 35929414
Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).
Papadaki MA, Messaritakis I, Fiste O, Souglakos J, Politaki E, Kotsakis A, Georgoulias V, Mavroudis D, Agelaki S. Papadaki MA, et al. Among authors: mavroudis d. Int J Mol Sci. 2021 Jan 18;22(2):925. doi: 10.3390/ijms22020925. Int J Mol Sci. 2021. PMID: 33477700 Free PMC article.
380 results